TAM
ALNY icon

Thematics Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Thematics Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.79M Buy
6,125
+7
+0.1% +$2.85K 0.13% 124
2025
Q2 		$2M Buy
+6,118
New +$1.69M 0.09% 126

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Thematics Asset Management's ALNY Position: Q3 2025 in Review

Thematics Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 0.11% in Q3 2025, buying an estimated $2.85K and bringing the position to 6,125 shares worth $2.79M. The position accounts for 0.13% of the portfolio, ranked #124.

Thematics Asset Management first reported a position in ALNY in Q2 2025 and has held it in 2 quarters since. 821 funds tracked by Wall St. Rank hold ALNY as of Q3 2025.

  • Thematics Asset Management held 6,125 shares of Alnylam Pharmaceuticals worth $2.79M as of Q3 2025.
  • Thematics Asset Management bought 7 Alnylam Pharmaceuticals shares in Q3 2025, an estimated $2.85K.
  • Alnylam Pharmaceuticals made up 0.13% of Thematics Asset Management's portfolio in Q3 2025, its #124 holding.
  • Thematics Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 2 quarters since.
  • 821 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2025.

Based on Thematics Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.